Pheochromocytoma primary prevention

Jump to: navigation, search

Pheochromocytoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pheochromocytoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pheochromocytoma primary prevention On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pheochromocytoma primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pheochromocytoma primary prevention

CDC on Pheochromocytoma primary prevention

Pheochromocytoma primary prevention in the news

Blogs on Pheochromocytoma primary prevention

Directions to Hospitals Treating Pheochromocytoma

Risk calculators and risk factors for Pheochromocytoma primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D[2]

Overview

Biochemical screening for family members of MEN2 patients is mandatory. Genetic testing should be performed in first-degree relatives of a patient with proven germline RET mutation.

Primary Prevention

Genetic testing should be performed in:[2]

References

  1. Aufforth RD, Ramakant P, Sadowski SM, Mehta A, Trebska-McGowan K, Nilubol N; et al. (2015). "Pheochromocytoma Screening Initiation and Frequency in von Hippel-Lindau Syndrome.". J Clin Endocrinol Metab. 100 (12): 4498–504. PMC 4667160Freely accessible. PMID 26451910. doi:10.1210/jc.2015-3045. 
  2. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH; et al. (2014). "Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline.". J Clin Endocrinol Metab. 99 (6): 1915–42. PMID 24893135. doi:10.1210/jc.2014-1498. 

Linked-in.jpg